Clinical Trial

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 5, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.
Trial Details
NCT Number NCT06673498
Lead Sponsor Anhui Provincial Hospital
Conditions Thrombocytopenia
Enrollment 60 participants
Start Date 2024-11-10
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-05